Dr. Leonidas Bleris (left), assistant professor of bioengineering at UT Dallas, and Richard Taplin Moore MS’11 helped create a new delivery system that may change gene therapy.
Bioengineers at The University of Texas at Dallas have created a novel gene-delivery system that shuttles a gene into a cell, but only for a temporary stay, providing a potential new gene-therapy strategy for treating disease.
The approach offers distinct advantages over other types of gene therapies under investigation, said Richard Taplin Moore MS’11, a doctoral student in bioengineering in the Erik Jonsson School of Engineering and Computer Science. He is lead author of a study describing the new technique in the Jan. 30 issue of the journal Nucleic Acids Research.
“In other gene therapy approaches, the therapeutic genetic messages being delivered can persist for a long time in the patient, potentially lasting for the patient’s entire lifetime,” Moore said. “This irreversibility is one reason gene therapies are so difficult to get approved.”
The UT Dallas study describes proof-of-concept experiments in which a gene carrying instructions for making a particular protein is ordered to self-destruct once the cell has “read” the instructions and made a certain quantity of the protein. In its experiments with isolated human kidney cells, the research team successfully delivered — and then destroyed — a test gene that makes a red fluorescent protein.
More research is needed to determine whether and how well the system might work in living organisms. But Moore said the ultimate goal is to refine the method to deliver genes that produce therapeutic proteins or drugs. The nature of the gene delivery system offers more control over how much protein the gene produces in cells or tissues. Because it does not alter the cell permanently, the method also sidesteps potential health problems that can occur if a gene is delivered to the wrong place in a cell’s genome.
“Our goal was to create a delivery system for therapeutic genes that would self-destruct, giving us more control over the delivered DNA by limiting the time it resides in cells,” Moore said.
Read more: Team Creates New Approach to Gene Therapy
The Latest on: Gene Therapy
via Google News
The Latest on: Gene Therapy
- Expert shares tips for safe subretinal delivery of gene therapyon May 25, 2022 at 12:35 pm
Best practices for safe subretinal delivery of gene therapy were presented at the Retina World Congress. “We have been continually looking at refining the technique and improving safety by avoiding ...
- FDA starts clock on review of CSL, UniQure gene therapyon May 25, 2022 at 9:14 am
The regulator agreed to assess the companies' data under priority review, setting up a decision on approval of the hemophilia B treatment in six months.
- Chester County gene therapy developer raises $112.8M five months after withdrawing IPO planson May 25, 2022 at 7:14 am
A Chester County cell and gene therapy company has raised $112.8 million in an oversubscribed stock sale about five months after withdrawing its plans for an IPO.
- Cell & Gene Therapy Market Share with Top Countries Data, Industry Trends, Growth, Opportunities and Forecast to 2022-2031on May 24, 2022 at 9:09 pm
The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2022–2031. The global cell and gene ...
- ASC Therapeutics Joins U.S. Consortium of Gene Therapy Partners Including the NIH and FDA to Accelerate Treatments for Rare Diseaseson May 24, 2022 at 5:00 pm
Public, private and non-profit organizations have joined forces to create a standardized approach that will reduce up-front costs and lower barriers to developing novel gene therapies for rare and ...
- Are We Any Closer to Intestinal Gene Therapy in Crohn's Disease?on May 24, 2022 at 7:28 am
Drs Peter Higgins and Judy Cho discuss recent success in sickle cell anemia and whether we're any closer to using intestinal gene therapy in Crohn's disease.
- CSL, uniQure's gene therapy for hemophilia B gets FDA priority reviewon May 24, 2022 at 6:05 am
The U.S. Food and Drug Administration ((FDA)) granted priority review to uniQure (QURE) and CSL's (CSLLY) gene therapy etranacogene dezaparvovec (EtranaDez) to treat hemophilia ...
- A Kansas man with a rare disorder spent decades advocating for gene therapy. It may never help himon May 24, 2022 at 6:00 am
Donavon Decker became, in more ways than one, an ambassador of limb girdle muscular dystrophy type 2D, a degenerative disorder. But decades after he participated in patient trials and fundraised for ...
- Gene Therapy Could Offer Treatment for Rare Neurological Disorderon May 24, 2022 at 1:44 am
Two recent discoveries co-led by scientists at Cedars-Sinai may help lead to new ways to treat patients with Allan-Herndon-Dudley syndrome (AHDS), a brain development disorder that causes severe ...
- PTC's first gene therapy gains European regulator's backingon May 20, 2022 at 9:05 am
The brain-infused treatment for a rare neurological disease will be one of only three gene therapies commercially available. Later this year, the company plans to ask for FDA approval.
via Bing News
